Codiak BioSciences, Cambridge, MA, USA.
Codiak BioSciences, Cambridge, MA, USA.
Curr Opin Biotechnol. 2022 Oct;77:102776. doi: 10.1016/j.copbio.2022.102776. Epub 2022 Aug 27.
Extracellular vesicles (EVs) have evolved across all phyla as an intercellular communication system. There are intrinsic advantages of leveraging this capability to deliver therapeutic cargo to treat disease, which have been demonstrated in numerous in vivo studies. As with other new modalities, the challenge has now shifted from proof of concept to developing reliable and efficient large-scale infrastructure to manufacture consistently pure and potent drug for broad-based patient access. This review focuses on how this challenge has been met with both existing and emerging technology platforms that are making impressive strides in the industrialization of EV manufacturing. In addition, we also highlight the gaps and opportunities that are beginning to be explored and addressed to hasten ushering in the era of therapeutic EVs.
细胞外囊泡 (EVs) 在所有生物门中作为一种细胞间通讯系统进化而来。利用这种能力将治疗性货物递送到治疗疾病具有内在的优势，这已在许多体内研究中得到证明。与其他新方法一样，现在的挑战已经从概念验证转移到开发可靠和高效的大规模基础设施，以制造一致纯净和有效的药物，为广泛的患者提供服务。本综述重点介绍了如何利用现有的和新兴的技术平台来应对这一挑战，这些平台在 EV 制造的工业化方面取得了令人瞩目的进展。此外，我们还强调了开始探索和解决的差距和机会，以加速治疗性 EV 时代的到来。
